Cargando…
Bispecific Antibody-Bound T Cells as a Novel Anticancer Immunotherapy
Chimeric antigen receptor T (CAR-T) cell therapy is one of the promising anticancer treatments. It shows a high overall response rate with complete response to blood cancer. However, there is a limitation to solid tumor treatment. Additionally, this currently approved therapy exhibits side effects s...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Society of Applied Pharmacology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424331/ https://www.ncbi.nlm.nih.gov/pubmed/35577765 http://dx.doi.org/10.4062/biomolther.2022.015 |